Pilot Randomized Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Depression in Patients with Non-Metastatic Breast Cancer (Depression)
Tele-IPT vs. Tele-Pharmacotherapy for Depression in Patients with Non-Metastatic Breast Cancer
Sponsor: Columbia University Velocity Grant
Enrolling: Male and Female Patients
Study Length: 12 Weeks
IRB Number: 8209
U.S. Govt. ID: NCT04973930
Contact: Alexandra Mackay: 646-774-8027 / alexandra.mackay@nyspi.columbia.edu
Additional Study Information: The goal of this research study is to compare evidence-based tele-therapies for patients with non-metastatic breast cancer and comorbid major depression. Participants will be randomly assigned (like by the flip of a coin) to receive twelve weeks of either interpersonal therapy (IPT) or pharmacotherapy with a serotonin reuptake inhibitor, either venlafaxine XR (Effexor) or escitalopram (Lexapro). All sessions will be held virtually via Zoom. Participants will be assessed by independent evaluators and will complete self-report questionnaires throughout the study. There will be a blood sample collected at the beginning and end of the study to measure C-reactive protein, a marker of inflammation elevated in both breast cancer and depression. Participants will be offered $50 compensation as a token of thanks for completing the final evaluation at Week 12.
This study is closed
John Markowitz, MD
Do You Qualify?
Are you currently depressed? Yes No
Have you been diagnosed with non-metastatic breast cancer in the last 10 years? Yes No
Do you have access to a smart phone, tablet, or computer with a camera and reliable internet connection? Yes No
Are you currently receiving treatment for depression? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Alexandra Mackay